Lots of questions out there...See twitter discussion found on Google as an example (includes comments from Zacks Investment Research biotech analyst) - https://twitter.com/JNapodano/status/556180872446373888 - Suggestion (and only half kidding) - At this critical juncture (not my wording as you will read in a moment)....Just edit the December 1-14 press release down to the following statements (didn't change a word) and re-release if all remains true to the word. Oh yes, change the date to January 26, 2015 - Montreal, Quebec, December 1, 2014 – Telesta Therapeutics Inc. (TSX: TST; PNK: BNHLF) (Formerly Bioniche Life Sciences Inc. TST:BNC) today affirmed that they remain on track with their internal objective of filing a Biologics License Application (BLA) for marketing approval with the US Food and Drug Administration (FDA) for MCNA1 prior to March 31, 2015. Dr. Michael Berendt, Chief Executive Officer and Chief Scientist noted that: At this critical juncture in our history, nothing is more important than achieving our ultimate goal of delivering to non-muscle invasive bladder cancer patients who have failed first line BCG therapy, a new and efficacious therapeutic option.” In parallel, Telesta expects to conclude their third party assessment of the market opportunity for MCNA, in the United States, in the weeks to come. This market assessment, where qualitative and quantitative primary market research was conducted with payers (managed care organizations/decision makers both from the private and public sector) and urologists (community urologists and key opinion leaders), will address issues such as market size, pricing/pricing strategy and market access context/reimbursement potential for MCNA. These data will be key in assisting Telesta to make informed decisions concerning overall market potential and optimal licensing/partnering and/or commercial development strategy. About Telesta Therapeutics Inc. Telesta Therapeutics Inc. is a late stage human therapeutics company with near term commercial potential focused on the manufacturing, marketing and licensing/acquisition of proprietary and innovative therapies for the global human health market. The Company’s primary goal is to develop and commercialize products that advance human health and increase shareholder value. For more information, please visit www.Bioniche.com (www.telestatherapeutics.com is coming soon!) - https://www.bioniche.com/news_item.cfm?id=2369